Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
P/S ratio for Exact Sciences Corporation (EXAS)
P/S ratio as of 2023: 5.33
According to Exact Sciences Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.33. At the end of 2022 the company had a P/S ratio of 4.19.
P/S ratio history for Exact Sciences Corporation from 1998 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 5.33 |
| 2022 | 4.19 |
| 2021 | 7.55 |
| 2020 | 13.43 |
| 2019 | 13.85 |
| 2018 | 16.97 |
| 2017 | 22.85 |
| 2016 | 13.76 |
| 2015 | 21.56 |
| 2014 | 1224.45 |
| 2013 | 191.37 |
| 2012 | 152.00 |
| 2011 | 102.43 |
| 2010 | 45.27 |
| 2009 | 23.36 |
| 2008 | -17.89 |
| 2007 | 29.56 |
| 2006 | 15.79 |
| 2005 | 13.66 |
| 2004 | 19.66 |
| 2003 | 65.97 |
| 2002 | 222.55 |
| 2001 | 3325.27 |
| 2000 | 21925890.00 |
| 1999 | 0.00 |
| 1998 | 0.00 |